MetaCap

Kalaris Therapeutics Inc. (KLRS)

NASDAQ: KLRSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.28-0.07 (-5.19%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KLRS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$30.47M
EPS (TTM)
-$1.84
52-week range
1.25 – 11.88
Day range
1.25 – 1.37
Volume / Avg
37.99K / 77.37K
Beta
—

52-week range

$1.25$11.88

KLRS stock today

Kalaris Therapeutics (KLRS) closed at $1.28 on Nov 20, down 5.19% (-$0.07), versus the S&P 500's 3.70% decline. Trading was light, with 37.99K shares changing hands, about 49% of the average daily volume. At this level, KLRS sits near the bottom of its 52-week range of $1.25 to $11.88: 89.2% below the high, set on Dec 18, 2025 and 2.4% above the low.

KLRS is down 84.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 81.7%. Kalaris Therapeutics has posted a net loss over the last twelve months (EPS of -$1.84), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Kalaris Therapeutics

Company profile

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Andrew Oxtoby
Headquarters
Berkeley Heights, NJ
Employees
20
IPO year
2020

Financial highlights

Full financials

Kalaris Therapeutics reported a net loss of $43.4 million, compared with a loss of $69.2 million a year earlier. Diluted earnings per share came in at -$2.85.

Kalaris Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-43.44M$-69.17M$-190.42M$-168.71M$-171.96M
EPS (diluted)$-2.85$-51.77$-42.09$-2.20$-2.74

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$18.71+1361.72%

  • Strong buy 2
  • Buy 5
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $7.00High $25.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.46 vs $-0.51
Surprise
+9.80%

KLRS news

All KLRS news

Kalaris Therapeutics peers

Health Care sector
KLRS peer companies
CompanyPrice% ChgMarket capCompare
CRBUCaribou Biosciences Inc.0.2843-8.44%$30.71Mvs KLRS
EXOZeXoZymes Inc.2.91-14.05%$27.42Mvs KLRS
LONALeonaBio Inc.2.02-17.89%$26.41Mvs KLRS
INMBINmune Bio Inc.0.827-7.50%$25.60Mvs KLRS
TILInstil Bio Inc.5.23-5.77%$35.47Mvs KLRS
PTHSPelthos Therapeutics Inc.6.38-8.73%$25.08Mvs KLRS
SAENGenenta Science S.p.A. ADR0.5074-9.39%$24.47Mvs KLRS
MGXMetagenomi Therapeutics Inc.0.565-7.95%$21.36Mvs KLRS

Indexes, lists and sector

Kalaris Therapeutics stock FAQ

What is Kalaris Therapeutics's stock price today?

KLRS last traded at $1.28 as of Nov 20, 4:00 PM EST, down 5.19% on the day. Prices are delayed at least 15 minutes.

Does Kalaris Therapeutics pay a dividend?

No. Kalaris Therapeutics does not currently pay a regular cash dividend.

Who is Kalaris Therapeutics's CEO?

Mr. Andrew Oxtoby is the chief executive officer of Kalaris Therapeutics Inc., which has about 20 employees.

Has KLRS ever split its stock?

Yes. The most recent KLRS stock split was a 1-for-23 split on Jan 16, 2025.

What is the KLRS 52-week high?

The 52-week high for KLRS is $11.88 and the 52-week low is $1.25. The stock is currently 89.2% below its high.

Compare KLRS